These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31599868)

  • 1. Qmiiz ODT--an orally disintegrating meloxicam tablet.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):151-152. PubMed ID: 31599868
    [No Abstract]   [Full Text] [Related]  

  • 2. IV meloxicam (Anjeso) for pain.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):100-102. PubMed ID: 32724022
    [No Abstract]   [Full Text] [Related]  

  • 3. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
    Dehghani H; Taheri A; Homayouni A
    Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavosomes, novel deformable liposomes for the co-delivery of anti-inflammatory compounds to skin.
    Zhang ZJ; Michniak-Kohn B
    Int J Pharm; 2020 Jul; 585():119500. PubMed ID: 32512226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abcg2 transporter affects plasma, milk and tissue levels of meloxicam.
    Garcia-Lino AM; Blanco-Paniagua E; Astorga-Simon EN; Alvarez-Fernandez L; Garcia-Mateos D; Alvarez-Fernandez I; Alvarez AI; Merino G
    Biochem Pharmacol; 2020 May; 175():113924. PubMed ID: 32217099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacometabolomics with a combination of PLS-DA and random forest algorithm analyses reveal meloxicam alters feline plasma metabolite profiles.
    Broughton-Neiswanger LE; Rivera-Velez SM; Suarez MA; Slovak JE; Hwang JK; Villarino NF
    J Vet Pharmacol Ther; 2020 Nov; 43(6):591-601. PubMed ID: 32562314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis.
    Prouse PJ; Bevis PJ; Bluhmki E; Distel M
    Clin Ther; 1996; 18(3):429-39. PubMed ID: 8829018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
    Ahmed IS; Shamma RN; Shoukri RA
    Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meloxicam.
    Fleischmann R; Iqbal I; Slobodin G
    Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meloxicam (Mobic): a review of its pharmacological and clinical profile].
    Ogino K; Saito K; Osugi T; Satoh H
    Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):391-7. PubMed ID: 12528470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
    Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk.
    Mishra DN; Vijaya Kumar SG
    Yakugaku Zasshi; 2006 Jul; 126(7):495-8. PubMed ID: 16819271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis.
    Huskisson EC; Ghozlan R; Kurthen R; Degner FL; Bluhmki E
    Br J Rheumatol; 1996 Apr; 35 Suppl 1():29-34. PubMed ID: 8630633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Particle engineering/different film approaches for earlier absorption of meloxicam.
    Farid M; El-Setouhy DA; El-Nabarawi MA; El-Bayomi T
    Drug Deliv; 2016 Sep; 23(7):2309-2317. PubMed ID: 25431841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients.
    Combe B; Vélicitat P; Garzón N; Bluhmki E
    Inflamm Res; 2001 Mar; 50 Suppl 1():S10-6. PubMed ID: 11339515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and optimization of a meloxicam/β-cyclodextrin complex for orally disintegrating tablet using statistical analysis.
    Ainurofiq A; Choiri S
    Pharm Dev Technol; 2018 Jun; 23(5):464-475. PubMed ID: 27875913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.
    Lou H; Liu M; Qu W; Hu Z; Brunson E; Johnson J; Almoazen H
    Drug Dev Ind Pharm; 2014 Jul; 40(7):910-8. PubMed ID: 23621768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence study of a novel orodispersible tablet of meloxicam in a porous matrix after single-dose administration in healthy volunteers.
    Radicioni M; Connolly S; Stroppolo F; Granata G; Loprete L; Leuratti C
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):234-43. PubMed ID: 23380429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.